Sofia Smith

bir ses eklendi Home

2022-12-21 11:18:47

In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.

Progressive Supranuclear Palsy (PSP) Therapies market Size, Share and Industry Trends by 2030

Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031Since John Steele, John Richardson, and Jerzy Olszewski first described PSP in 1964, the neuroscience community has been on the lookout to find a “miracle molecule” or an “elixir” that can cure patients diagnosed with this debilitating disease.With more than 2,000 research studies published...

·3K Views ·0 önizleme

Katıl

Dosya

Sofia Smith

Progressive Supranuclear Palsy (PSP) Therapies market Size, Share and Industry Trends by 2030